Business Relations Table - o4.fyi ()

Anmelden Gast|Guest
Beispiel: brt.php?search=wide&s=wide&p=adjective&o=wideness

Domain-Statistiken für "genethon.com"

216
Business Relations
213
Eindeutige Domains
20
Gefundene Einträge
BR-Relations: 216
From Domain Role To Domain Path Aktionen
/malattia/sindrome-di-wiskott-aldrich/
/2026/01/16/telegram-seo-linkk-order-seo-backlinks-homepage-4-8/
/category/seo-linkk-order/
/masslinker-com-software-to-publish-your-own-2-2/
/e6bb759-gene-therapy-CRISPR/
/fr/challenges/apogeebio-2022/pages/partners
/category/masslinker/
/genethon-receives-the-2012-prix-galien-france/
/decree-advanced-therapy-medicinal-products-a-new-milestone-for-the-afm-telethon-and-laboratory-genethon/
/first-promising-results-towards-the-treatment-of-myotubular-myopathy/
/genethons-teams-present-their-progress-at-the-asgct-meeting/
/genethon-presents-significant-advances-in-gene-therapy-at-european-society-for-gene-and-cell-therapy-oct-19-22-2021/
/genethons-lentiviral-vector-based-gene-therapy-demonstrates-long-term-safety-and-efficacy-for-wiskott-aldrich-syndrome/
/genethons-lentiviral-vector-based-gene-therapy-demonstrates-long-term-safety-and-efficacy-for-wiskott-aldrich-syndrome/
/genethons-lentiviral-vector-based-gene-therapy-demonstrates-long-term-safety-and-efficacy-for-wiskott-aldrich-syndrome/
/genethon-joins-u-s-bespoke-gene-therapy-consortium-dedicated-to-finding-treatments-for-ultra-rare-diseases/
/genethon-to-present-its-latest-gene-therapy-research-advancements-in-neuromuscular-diseases-at-the-international-myology-2022-congress/
/iltoo-pharma-and-the-mirocals-consortium-announce-the-signing-of-licence-agreement-for-the-development-of-low-dose-interleukin-2-as-a-potential-treatment-for-amyotrophic-lateral-sclerosis-als/
/iltoo-pharma-and-the-mirocals-consortium-announce-the-signing-of-licence-agreement-for-the-development-of-low-dose-interleukin-2-as-a-potential-treatment-for-amyotrophic-lateral-sclerosis-als/
/iltoo-pharma-and-the-mirocals-consortium-announce-the-signing-of-licence-agreement-for-the-development-of-low-dose-interleukin-2-as-a-potential-treatment-for-amyotrophic-lateral-sclerosis-als/